Deflazacort versus prednisone treatment for Duchenne muscular dystrophy: a meta‐analysis of disease progression rates in recent multicenter clinical trials

Craig M. McDonald,G. Sajeev,Z. Yao,Erin McDonnell,Gary L. Elfring,Márcio Souza,Stuart W. Peltz,Basil T. Darras,Perry B. Shieh,David A. Cox,John Landry,James Signorovitch

Deflazacort versus prednisone treatment for Duchenne muscular dystrophy: a meta‐analysis of disease progression rates in recent multicenter clinical trials

2019

Craig M. McDonald
G. Sajeev
Z. Yao
Erin McDonnell
Gary L. Elfring
Márcio Souza
Stuart W. Peltz
Basil T. Darras
Perry B. Shieh
David A. Cox
John Landry
James Signorovitch

Introduction In this study we characterized disease progression over 48 weeks among boys receiving deflazacort vs prednisone/prednisolone placebo arm treatment in two recent Duchenne muscular dystrophy (DMD) clinical trials.

Keywords:

Prednisone treatment
Clinical trial
Duchenne muscular dystrophy
Diabetes mellitus
Deflazacort
Internal medicine
Anatomy
Disease
Meta-analysis
Medicine
Prednisone
Corticosteroid
Ambulatory
Prednisolone
Confidence interval
Placebo

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations